William Edward Boden, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myocardial Ischemia | 78 | 2024 | 2133 | 11.480 |
Why?
|
| Coronary Artery Disease | 97 | 2024 | 6506 | 8.260 |
Why?
|
| Angioplasty, Balloon, Coronary | 56 | 2021 | 1724 | 5.810 |
Why?
|
| Myocardial Revascularization | 42 | 2024 | 794 | 5.770 |
Why?
|
| Myocardial Infarction | 132 | 2024 | 11476 | 4.750 |
Why?
|
| Coronary Artery Bypass | 47 | 2023 | 2193 | 4.650 |
Why?
|
| Angina Pectoris | 42 | 2023 | 959 | 4.650 |
Why?
|
| Cardiovascular Agents | 35 | 2024 | 842 | 4.390 |
Why?
|
| Niacin | 14 | 2024 | 117 | 4.340 |
Why?
|
| Cholesterol, HDL | 20 | 2023 | 1812 | 3.120 |
Why?
|
| Hypolipidemic Agents | 16 | 2019 | 609 | 3.120 |
Why?
|
| Angina, Unstable | 33 | 2022 | 890 | 3.050 |
Why?
|
| Acute Coronary Syndrome | 30 | 2024 | 2194 | 2.700 |
Why?
|
| Coronary Disease | 50 | 2023 | 5921 | 2.570 |
Why?
|
| Hypertriglyceridemia | 6 | 2024 | 292 | 2.520 |
Why?
|
| Platelet Aggregation Inhibitors | 35 | 2021 | 2746 | 2.360 |
Why?
|
| Cardiovascular Diseases | 37 | 2024 | 15521 | 1.950 |
Why?
|
| Electrocardiography | 72 | 2018 | 6387 | 1.950 |
Why?
|
| Coronary Angiography | 50 | 2024 | 4507 | 1.940 |
Why?
|
| Dyslipidemias | 7 | 2022 | 870 | 1.860 |
Why?
|
| Calcium Channel Blockers | 16 | 2020 | 691 | 1.630 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 20 | 2024 | 3245 | 1.510 |
Why?
|
| Ischemia | 16 | 2023 | 1889 | 1.500 |
Why?
|
| Vasodilator Agents | 12 | 2017 | 989 | 1.500 |
Why?
|
| Diltiazem | 21 | 2001 | 131 | 1.490 |
Why?
|
| Eicosapentaenoic Acid | 8 | 2024 | 561 | 1.480 |
Why?
|
| Myocardial Perfusion Imaging | 9 | 2022 | 659 | 1.300 |
Why?
|
| Nitrates | 8 | 2017 | 260 | 1.290 |
Why?
|
| Practice Guidelines as Topic | 27 | 2024 | 7400 | 1.280 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 9 | 2019 | 1130 | 1.280 |
Why?
|
| Adrenergic beta-Antagonists | 23 | 2020 | 1241 | 1.280 |
Why?
|
| Randomized Controlled Trials as Topic | 44 | 2024 | 10218 | 1.240 |
Why?
|
| Coronary Vessels | 12 | 2022 | 3111 | 1.220 |
Why?
|
| Drug-Eluting Stents | 7 | 2016 | 681 | 1.190 |
Why?
|
| Ticlopidine | 15 | 2016 | 730 | 1.190 |
Why?
|
| Exercise Test | 26 | 2020 | 2165 | 1.170 |
Why?
|
| Humans | 403 | 2024 | 761222 | 1.160 |
Why?
|
| Terminology as Topic | 2 | 2024 | 1528 | 1.120 |
Why?
|
| Triglycerides | 14 | 2024 | 2457 | 1.110 |
Why?
|
| Treatment Outcome | 107 | 2024 | 64681 | 1.090 |
Why?
|
| Coronary Stenosis | 10 | 2018 | 802 | 1.070 |
Why?
|
| Atherosclerosis | 14 | 2024 | 3407 | 1.040 |
Why?
|
| Thrombolytic Therapy | 13 | 2018 | 2055 | 0.970 |
Why?
|
| Hyperlipidemias | 4 | 2024 | 771 | 0.940 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 11 | 2011 | 578 | 0.900 |
Why?
|
| Nitroglycerin | 3 | 2015 | 330 | 0.850 |
Why?
|
| Risk Assessment | 44 | 2024 | 24022 | 0.850 |
Why?
|
| Drug Therapy, Combination | 33 | 2018 | 6304 | 0.840 |
Why?
|
| Aspirin | 16 | 2018 | 3129 | 0.840 |
Why?
|
| Fibrinolytic Agents | 9 | 2014 | 2075 | 0.810 |
Why?
|
| Fractional Flow Reserve, Myocardial | 3 | 2022 | 345 | 0.800 |
Why?
|
| Vasodilation | 2 | 2017 | 966 | 0.780 |
Why?
|
| Secondary Prevention | 10 | 2018 | 1472 | 0.770 |
Why?
|
| Clinical Trials as Topic | 23 | 2024 | 8002 | 0.770 |
Why?
|
| Coronary Circulation | 5 | 2021 | 1611 | 0.750 |
Why?
|
| Risk Factors | 84 | 2024 | 74241 | 0.740 |
Why?
|
| Diabetes Mellitus | 9 | 2023 | 5842 | 0.730 |
Why?
|
| Cholesterol, LDL | 14 | 2023 | 2380 | 0.720 |
Why?
|
| Renal Insufficiency, Chronic | 10 | 2022 | 2254 | 0.690 |
Why?
|
| Coronary Occlusion | 1 | 2023 | 304 | 0.670 |
Why?
|
| Time Factors | 56 | 2024 | 39957 | 0.670 |
Why?
|
| Stents | 12 | 2021 | 3177 | 0.670 |
Why?
|
| Translating | 1 | 2020 | 143 | 0.660 |
Why?
|
| Disease Management | 6 | 2022 | 2507 | 0.650 |
Why?
|
| 1-Alkyl-2-acetylglycerophosphocholine Esterase | 1 | 2019 | 127 | 0.630 |
Why?
|
| Exercise Tolerance | 5 | 2018 | 838 | 0.620 |
Why?
|
| Delivery of Health Care | 6 | 2021 | 5333 | 0.610 |
Why?
|
| Vascular Diseases | 3 | 2023 | 1160 | 0.610 |
Why?
|
| Unnecessary Procedures | 1 | 2021 | 418 | 0.600 |
Why?
|
| Middle Aged | 159 | 2024 | 220858 | 0.590 |
Why?
|
| Syndrome | 14 | 2021 | 3271 | 0.590 |
Why?
|
| Aged | 131 | 2024 | 169292 | 0.580 |
Why?
|
| Lipoproteins | 3 | 2018 | 877 | 0.580 |
Why?
|
| Risk Reduction Behavior | 6 | 2022 | 1111 | 0.570 |
Why?
|
| Myocardial Reperfusion | 3 | 2008 | 339 | 0.570 |
Why?
|
| Male | 184 | 2024 | 360703 | 0.560 |
Why?
|
| Anticholesteremic Agents | 8 | 2018 | 968 | 0.560 |
Why?
|
| Diabetes Mellitus, Type 2 | 14 | 2023 | 12159 | 0.550 |
Why?
|
| Female | 195 | 2024 | 392552 | 0.540 |
Why?
|
| Delayed-Action Preparations | 8 | 2019 | 961 | 0.530 |
Why?
|
| Reimbursement Mechanisms | 1 | 2021 | 667 | 0.510 |
Why?
|
| Quality of Life | 28 | 2024 | 13367 | 0.500 |
Why?
|
| Tyrosine | 4 | 2008 | 1422 | 0.490 |
Why?
|
| Prognosis | 39 | 2024 | 29688 | 0.480 |
Why?
|
| Plaque, Atherosclerotic | 2 | 2024 | 1535 | 0.480 |
Why?
|
| Thrombosis | 6 | 2018 | 2944 | 0.470 |
Why?
|
| Health Care Reform | 2 | 2017 | 1247 | 0.470 |
Why?
|
| Insulin | 3 | 2016 | 6588 | 0.470 |
Why?
|
| Diabetic Angiopathies | 4 | 2015 | 805 | 0.460 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 2 | 2016 | 152 | 0.450 |
Why?
|
| Testosterone | 3 | 2023 | 2472 | 0.440 |
Why?
|
| Chelation Therapy | 1 | 2013 | 77 | 0.440 |
Why?
|
| Health Expenditures | 2 | 2019 | 2362 | 0.440 |
Why?
|
| Kaplan-Meier Estimate | 18 | 2020 | 6486 | 0.430 |
Why?
|
| Coronary Restenosis | 3 | 2012 | 396 | 0.430 |
Why?
|
| Heart Rate | 15 | 2018 | 4197 | 0.420 |
Why?
|
| Cardiomyopathies | 2 | 2023 | 2021 | 0.420 |
Why?
|
| Follow-Up Studies | 42 | 2024 | 39127 | 0.420 |
Why?
|
| Peripheral Arterial Disease | 4 | 2019 | 1275 | 0.420 |
Why?
|
| Acetanilides | 3 | 2011 | 169 | 0.410 |
Why?
|
| Heart Diseases | 4 | 2012 | 2795 | 0.410 |
Why?
|
| Androgens | 1 | 2020 | 1283 | 0.410 |
Why?
|
| Combined Modality Therapy | 14 | 2018 | 8519 | 0.400 |
Why?
|
| Survival Rate | 17 | 2023 | 12728 | 0.400 |
Why?
|
| Cardiology | 6 | 2023 | 1693 | 0.400 |
Why?
|
| Health Status | 12 | 2024 | 4077 | 0.400 |
Why?
|
| Chelating Agents | 1 | 2013 | 383 | 0.400 |
Why?
|
| Glucose Intolerance | 1 | 2016 | 575 | 0.390 |
Why?
|
| Hypoglycemic Agents | 5 | 2019 | 3089 | 0.390 |
Why?
|
| Multicenter Studies as Topic | 10 | 2010 | 1702 | 0.380 |
Why?
|
| Cause of Death | 7 | 2023 | 3688 | 0.380 |
Why?
|
| Double-Blind Method | 25 | 2023 | 12341 | 0.380 |
Why?
|
| Severity of Illness Index | 23 | 2024 | 15841 | 0.370 |
Why?
|
| Coronary Care Units | 4 | 2008 | 235 | 0.370 |
Why?
|
| Piperazines | 6 | 2013 | 2522 | 0.370 |
Why?
|
| Predictive Value of Tests | 18 | 2024 | 15308 | 0.370 |
Why?
|
| Verapamil | 3 | 2001 | 242 | 0.360 |
Why?
|
| Goals | 2 | 2024 | 710 | 0.350 |
Why?
|
| Endpoint Determination | 5 | 2011 | 590 | 0.350 |
Why?
|
| Lipoproteins, HDL | 5 | 2018 | 675 | 0.340 |
Why?
|
| Simvastatin | 6 | 2019 | 346 | 0.340 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 8 | 2019 | 1504 | 0.340 |
Why?
|
| Lipid Metabolism | 1 | 2018 | 1893 | 0.340 |
Why?
|
| Stroke | 22 | 2024 | 9721 | 0.330 |
Why?
|
| Ventricular Dysfunction, Left | 8 | 2023 | 2131 | 0.320 |
Why?
|
| Coronary Thrombosis | 4 | 2011 | 440 | 0.320 |
Why?
|
| Gemfibrozil | 4 | 2003 | 30 | 0.310 |
Why?
|
| Creatine Kinase | 15 | 2024 | 684 | 0.310 |
Why?
|
| Perioperative Care | 2 | 2017 | 1037 | 0.310 |
Why?
|
| Evidence-Based Medicine | 8 | 2024 | 3691 | 0.310 |
Why?
|
| Anticoagulants | 6 | 2009 | 4795 | 0.300 |
Why?
|
| Tachycardia, Supraventricular | 1 | 2011 | 273 | 0.300 |
Why?
|
| Physician-Patient Relations | 1 | 2021 | 3253 | 0.300 |
Why?
|
| Drugs, Investigational | 1 | 2010 | 212 | 0.300 |
Why?
|
| Echocardiography, Stress | 4 | 2015 | 135 | 0.300 |
Why?
|
| Cost-Benefit Analysis | 11 | 2023 | 5493 | 0.300 |
Why?
|
| United States | 37 | 2023 | 72341 | 0.300 |
Why?
|
| Hospitals, Veterans | 4 | 2002 | 395 | 0.290 |
Why?
|
| Patient Admission | 3 | 2013 | 1365 | 0.280 |
Why?
|
| Laboratories | 1 | 2011 | 462 | 0.280 |
Why?
|
| Exercise Therapy | 1 | 2014 | 922 | 0.280 |
Why?
|
| Fibrinolysis | 2 | 2007 | 332 | 0.280 |
Why?
|
| Survival Analysis | 18 | 2020 | 10088 | 0.270 |
Why?
|
| Hyperglycemia | 2 | 2013 | 1375 | 0.270 |
Why?
|
| Enzyme Inhibitors | 5 | 2014 | 3702 | 0.270 |
Why?
|
| Hypogonadism | 2 | 2023 | 798 | 0.260 |
Why?
|
| Decision Trees | 4 | 2020 | 505 | 0.260 |
Why?
|
| Heart Conduction System | 2 | 2001 | 1008 | 0.260 |
Why?
|
| Guideline Adherence | 7 | 2019 | 2220 | 0.260 |
Why?
|
| Stroke Volume | 7 | 2016 | 5521 | 0.260 |
Why?
|
| Tricuspid Valve Insufficiency | 2 | 2024 | 353 | 0.260 |
Why?
|
| Postoperative Complications | 7 | 2017 | 15637 | 0.250 |
Why?
|
| Pacemaker, Artificial | 3 | 2024 | 807 | 0.250 |
Why?
|
| Registries | 6 | 2021 | 8246 | 0.250 |
Why?
|
| Digoxin | 3 | 2000 | 246 | 0.250 |
Why?
|
| Television | 1 | 2008 | 407 | 0.250 |
Why?
|
| Hypertension | 10 | 2023 | 8536 | 0.240 |
Why?
|
| Tachycardia, Ventricular | 2 | 2011 | 1305 | 0.240 |
Why?
|
| United States Department of Veterans Affairs | 7 | 2022 | 930 | 0.240 |
Why?
|
| Anti-Arrhythmia Agents | 4 | 2017 | 774 | 0.240 |
Why?
|
| Thiophenes | 3 | 2013 | 569 | 0.230 |
Why?
|
| Angiotensin Receptor Antagonists | 3 | 2021 | 1039 | 0.230 |
Why?
|
| Mitral Valve Insufficiency | 2 | 2024 | 1400 | 0.230 |
Why?
|
| Microcirculation | 1 | 2009 | 1280 | 0.230 |
Why?
|
| Recurrence | 18 | 2018 | 8457 | 0.230 |
Why?
|
| Vascular Surgical Procedures | 2 | 2023 | 1489 | 0.220 |
Why?
|
| Government Regulation | 1 | 2008 | 523 | 0.220 |
Why?
|
| Hemorrhage | 9 | 2024 | 3422 | 0.220 |
Why?
|
| History, 21st Century | 4 | 2018 | 1567 | 0.210 |
Why?
|
| Antihypertensive Agents | 3 | 2019 | 2019 | 0.210 |
Why?
|
| Acute Disease | 13 | 2005 | 7226 | 0.210 |
Why?
|
| Lipids | 2 | 2009 | 3331 | 0.210 |
Why?
|
| Insurance, Health | 2 | 2019 | 2493 | 0.200 |
Why?
|
| Incidence | 12 | 2021 | 21366 | 0.200 |
Why?
|
| Cardiology Service, Hospital | 1 | 2004 | 240 | 0.200 |
Why?
|
| Aged, 80 and over | 22 | 2024 | 58952 | 0.200 |
Why?
|
| Blood Glucose | 2 | 2016 | 6392 | 0.200 |
Why?
|
| Hospitals, Urban | 1 | 2004 | 500 | 0.200 |
Why?
|
| Proportional Hazards Models | 15 | 2020 | 12474 | 0.200 |
Why?
|
| Hippocratic Oath | 1 | 2021 | 16 | 0.190 |
Why?
|
| Heart Failure | 9 | 2023 | 11701 | 0.190 |
Why?
|
| Chronic Disease | 10 | 2024 | 9319 | 0.190 |
Why?
|
| Glomerular Filtration Rate | 2 | 2021 | 2182 | 0.190 |
Why?
|
| History, 20th Century | 4 | 2018 | 2765 | 0.190 |
Why?
|
| Prospective Studies | 24 | 2021 | 54437 | 0.190 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2021 | 10756 | 0.180 |
Why?
|
| Cardiac Resynchronization Therapy | 2 | 2024 | 558 | 0.180 |
Why?
|
| Defibrillators, Implantable | 2 | 2024 | 1492 | 0.180 |
Why?
|
| Comorbidity | 11 | 2019 | 10516 | 0.180 |
Why?
|
| Drug Therapy | 2 | 2010 | 503 | 0.180 |
Why?
|
| Ontario | 2 | 2024 | 398 | 0.180 |
Why?
|
| Felodipine | 2 | 1997 | 3 | 0.170 |
Why?
|
| Phenethylamines | 1 | 2000 | 95 | 0.170 |
Why?
|
| Peptides | 4 | 2008 | 4353 | 0.170 |
Why?
|
| Blood Platelets | 1 | 2010 | 2477 | 0.160 |
Why?
|
| Brugada Syndrome | 2 | 2011 | 93 | 0.160 |
Why?
|
| Referral and Consultation | 3 | 2022 | 3608 | 0.160 |
Why?
|
| Risk | 8 | 2018 | 9616 | 0.160 |
Why?
|
| Cardiomegaly | 3 | 1992 | 590 | 0.160 |
Why?
|
| Preventive Medicine | 2 | 2017 | 245 | 0.160 |
Why?
|
| Pyridones | 1 | 2024 | 809 | 0.160 |
Why?
|
| Troponin | 4 | 2011 | 504 | 0.160 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2019 | 278 | 0.160 |
Why?
|
| Immunoglobulin Fab Fragments | 3 | 2008 | 445 | 0.160 |
Why?
|
| Isoenzymes | 11 | 2005 | 1682 | 0.150 |
Why?
|
| Data Interpretation, Statistical | 2 | 2007 | 2691 | 0.150 |
Why?
|
| Creatine Kinase, MB Form | 3 | 2020 | 202 | 0.150 |
Why?
|
| Research Design | 8 | 2019 | 6180 | 0.150 |
Why?
|
| Exercise | 4 | 2018 | 5874 | 0.150 |
Why?
|
| Diagnosis, Differential | 5 | 2011 | 12976 | 0.150 |
Why?
|
| Sodium Channel Blockers | 1 | 2019 | 172 | 0.150 |
Why?
|
| Hospitals | 1 | 2011 | 3881 | 0.150 |
Why?
|
| Enalapril | 2 | 1997 | 310 | 0.150 |
Why?
|
| Veterans | 5 | 2022 | 2656 | 0.150 |
Why?
|
| Eating | 1 | 2024 | 1535 | 0.150 |
Why?
|
| Hormone Replacement Therapy | 1 | 2023 | 751 | 0.140 |
Why?
|
| Thoracic Surgery | 1 | 2024 | 722 | 0.140 |
Why?
|
| Cohort Studies | 10 | 2023 | 41496 | 0.140 |
Why?
|
| Blood Pressure | 10 | 2019 | 8479 | 0.140 |
Why?
|
| Coronary Sinus | 1 | 2017 | 84 | 0.140 |
Why?
|
| Health Services Misuse | 1 | 2019 | 244 | 0.140 |
Why?
|
| Oxygen Consumption | 2 | 2017 | 1867 | 0.140 |
Why?
|
| Brain Ischemia | 4 | 2018 | 3032 | 0.140 |
Why?
|
| Internationality | 1 | 2022 | 999 | 0.130 |
Why?
|
| Life Style | 4 | 2019 | 3907 | 0.130 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2001 | 1092 | 0.130 |
Why?
|
| Outpatients | 2 | 2021 | 1598 | 0.130 |
Why?
|
| Age Factors | 9 | 2019 | 18384 | 0.130 |
Why?
|
| Hospital Mortality | 6 | 2013 | 5295 | 0.130 |
Why?
|
| Odds Ratio | 6 | 2016 | 9652 | 0.130 |
Why?
|
| Administration, Sublingual | 1 | 2015 | 59 | 0.130 |
Why?
|
| Canada | 6 | 2015 | 2125 | 0.130 |
Why?
|
| Brachiocephalic Veins | 1 | 2015 | 21 | 0.130 |
Why?
|
| Benzazepines | 3 | 1986 | 310 | 0.130 |
Why?
|
| Disease Progression | 6 | 2011 | 13511 | 0.120 |
Why?
|
| Meta-Analysis as Topic | 3 | 2001 | 1381 | 0.120 |
Why?
|
| Azetidines | 2 | 2013 | 142 | 0.120 |
Why?
|
| Tablets | 1 | 2015 | 148 | 0.120 |
Why?
|
| Bioprosthesis | 2 | 1994 | 591 | 0.120 |
Why?
|
| Haptoglobins | 1 | 2016 | 165 | 0.120 |
Why?
|
| Chi-Square Distribution | 5 | 2013 | 3418 | 0.120 | |